| Objective: To observe the effects of carrelizumab combine with transcatheter arterial chemoembolization (TACE) on tumor markers, angiogenic factors, serum programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) in patients with hepatocellular carcinoma (HCC) with microvascular invasion. Methods: According to the random number table method, 121 HCC patients with microvascular invasion who were admitted to our hospital from June 2021 to July 2023 were divided into control group (n=60, receiving radical resection of liver cancer and TACE treatment) and study group (n=61, receiving carrelizumab treatment on the basis of control group). The efficacy, serum tumor marker levels [carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), carbohydrate antigen 199 (CA199), abnormal prothrombin (PIVKA-II)], angiogenesis factor levels [vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor 2 (VEGF-R2), angiopoietin-2 (Ang-2)], serum PD-1 and PD-L1 levels were compared between two groups, and the incidence of adverse reactions during treatment was observed. Results: Compared with control group, the total clinical effective rate in study group was higher (P<0.05). Compared with control group after treatment, CEA, AFP, CA199, PIVKA-II, VEGF, VEGF-R2, Ang-2, PD-1 and PD-L1 in study group were lower (P<0.05). There was no difference in the incidence of adverse reactions between two groups (P>0.05). Conclusion: Carrelizumab combine with TACE in the treatment of HCC patients with microvascular invasion, which can effectively improve the serum tumor markers of patients, inhibit angiogenesis and reduce serum PD-1 and PD-L1 levels, and effectively control disease progression. |
